- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07944378
A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia (LOHKALT)
A Phase IV, Multicentre, Non-comparative, Open-label Study Evaluating the Safety and Effectiveness of Lokelma (Sodium Zirconium Cyclosilicate [SZC]) Administered Orally for the Treatment of Indian Patients With Hyperkalaemia
This is a Phase IV, multicentre, open-label, non-comparative study evaluating Lokelma (sodium zirconium cyclosilicate, SZC) in approximately 100 Indian adults with mild to moderate hyperkalaemia.
Studieoversikt
Detaljert beskrivelse
The primary objective is to assess safety through treatment-emergent adverse events, serious adverse events and discontinuations due to adverse events. Secondary objectives are to assess effectiveness of Lokelma through serum potassium reduction, achievement and maintenance of normokalaemia, while an exploratory objective focuses on continuation or initiation of RAAS inhibitor therapy. Each participant is followed for approximately 3.5 months, including treatment and a safety follow-up seven days after the final dose.
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studiesteder
-
-
-
Ahmedabad, India, 380052
- Rekruttering
- Research Site
-
Ahmedabad, India, 380013
- Rekruttering
- Research Site
-
Kolkata, India, 700020
- Rekruttering
- Research Site
-
Secunderabad, India, 500003
- Rekruttering
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
• Participant must be ≥ 18 years of age, at the time of signing the informed consent.
- Participants with mild to moderate hyperkalaemia- the potassium values between 5.1 to 6.4 mmol/L inclusive, at screening (Day 0)
- Ability to have repeated blood draws or effective venous catheterisation.
- Contraceptive use by females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. i) FOCBP must be using two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at screening. The female participants should be on stable on their chosen method of birth control for minimum of one month before entering the study and willing to remain on the birth control until 7 days after the last dose. ii) Female participants who are surgically sterile or those who are post-menopausal (if they have been amenorrhoeic for 12 months prior to the planned date of screening without an alternative medical cause) are not considered to be of child-bearing potential.
- Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
Exclusion Criteria:
-
As judged by the investigator, any evidence of oedema which in the investigator's opinion makes it undesirable for the participant to participate in the study.
- Patients undergoing haemodialysis or a prospective candidate for haemodialysis.
- Pseudo hyperkalaemia signs and symptoms, such as excessive fist clenching haemolysed blood specimen, severe leucocytosis or thrombocytosis.
- Participants with a life expectancy of < 12 months.
- Participants who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the participants' tasks associated with the protocol.
- Women who are pregnant, lactating, or planning to become pregnant.
- Participants with diabetic ketoacidosis.
- Presence of any condition which, in the opinion of the investigator, places the participant at undue risk.
- Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia.
- Participants with cardiac arrhythmias requiring immediate treatment.
- Participants with history of QT prolongation associated with other medications that required discontinuation of that medication.
- Participants with congenital long QT syndrome.
- Participants treated with lactulose, rifaximin or other non-absorbed antibiotics for hyperammonaemia within the last 7 days.
- Participants treated with resins (such as sevelamer acetate), calcium acetate, calcium carbonate, or lanthanum carbonate, within the last 7 days.
- Participants treated with SPS or SZC (microporous, fractionated, protonated zirconium silicate), CPS or patiromer within the last 7 days.
- Known hypersensitivity or previous anaphylaxis to SZC or to components or any of the excipients of the product.
- Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.
- Prior (within last 1 month) and ongoing participation in another clinical trial, observational study, and real-world evidence study.
- Positive hepatitis C antibody, hepatitis B virus surface antigen, or hepatitis B virus core antibody, at screening.
- Known to have tested positive for HIV.
- Documented glomerular filtration rate < 15 mL/min/1.73 m2 within 90 days before study entry.
- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
- Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Intervention
Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g |
Sodium Zirconium Cyclosilicate SZC Lokelma 5g and 10 g |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of TEAEs, SAEs, and DAEs.
Tidsramme: Day 86
|
Number and proportion of participants with TEAEs SAEs, and DAEs. Incidence rates summarised by patients with events per 100 patient-years. |
Day 86
|
|
Causal relationship of TEAEs, SAEs, and DAEs
Tidsramme: Day 86
|
Nature, intensity and causal relationship of TEAEs, SAEs, and DAEs |
Day 86
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Exponential rate of change in S-K values
Tidsramme: Day 4
|
Rate of Change in S-K values |
Day 4
|
|
Proportion of participants who achieve normokalaemia
Tidsramme: Day 4
|
Number of study subjects achieving normal potassium levels |
Day 4
|
|
Mean change and mean percent change from baseline in S-K values
Tidsramme: Day 86
|
Mean change and mean percent change from baseline in S-K values over time until EOT |
Day 86
|
|
Proportions of participants maintaining normokalaemia
Tidsramme: Day 86
|
Number participants maintaining normal potassium levels at EOT |
Day 86
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- D9480L00025
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tilgangskriterier for IPD-deling
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .